title: Successful use of infliximab therapy in sight-threatening corticosteroid-resistant Vogt-Koyanagi-Harada disease.
abstract: OBJECTIVE
  To report an experience with infliximab in severe corticosteroid-resistant Vogt-Koyanagi-Harada (VKH) disease.
  
  
  METHODS
  Interventional case series.
  
  
  METHODS
  The medical records of 2 adult patients were reviewed.
  
  
  RESULTS
  Both patients had a visual acuity reduced to hand motion perception bilaterally after 1 month of high-dose corticosteroid therapy, due to multiple exudative retinal detachment involving the fovea. Visual acuity and OCT findings improved immediately after the first infliximab infusion, retinal detachments fully resolved after 1 month and visual acuity returned to normal within 6 months. Despite a negative pretreatment screening, one patient developed multivisceral tuberculosis, which led to infliximab discontinuation after the 7th infusion and was cured by a 9-month ambulatory antibiotic regimen. The other patient received 11 well-tolerated infliximab infusions. Respectively, 9 and 4 months after infliximab discontinuation both patients had normal vision and OCT findings.
  
  
  CONCLUSIONS
  Infliximab showed tremendous therapeutic efficacy in sight-threatening corticosteroid-resistant VKH disease.
authors.forename: Mathieu
authors.initials: M
authors.lastname: Zmuda
authors.forename: Kiet Phong
authors.initials: KP
authors.lastname: Tiev
authors.forename: Juliette
authors.initials: J
authors.lastname: Knoeri
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Héron
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003937:Diagnosis, Differential; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D000069285:Infliximab; D008875:Middle Aged; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014607:Uveomeningoencephalitic Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D014792:Visual Acuity; D055815:Young Adult
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab